Advanced Filters
noise

chickenpox-varicella-zoster-infection Clinical Trials

A listing of chickenpox-varicella-zoster-infection medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 23 clinical trials

VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination

To evaluate the effect of intramuscular RZV vaccine on VZV-specific skin TRM and circulating T-cells

30 - 100 years of age Both Phase 4
U US GSK Clinical Trials Call Center

A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant

The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2 doses of PED-HZ/su, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in immunocompromised paediatric renal transplant recipients aged 1-17 years

1 - 17 years of age Both Phase 2

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune system's reaction) of the study vaccine called Varicella Zoster Virus modRNA (VZV modRNA). We are seeking for healthy participants who are between 50 and 69 …

50 - 69 years of age Both Phase 2

Nudging Patients to Increase Shingles Vaccination

The purpose of this study is to test whether messages encouraging patients to ask about a Shingrix vaccine at an upcoming appointment will increase Shingrix vaccination rates. The study will also test which of several message versions is most effective.

50 - 100 years of age Both Phase N/A
S Scott A Halperin, MD

A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years

This is a randomized, observer blind and controlled study. Participants in low-dose and high-dose IM group will be randomized in a ratio of 2:1 to receive either the investigational product or the control. Participants in the IH group will receive either inhaled investigational product or saline in a ratio of …

50 - 65 years of age Both Phase 1
H Hantong Hu, MD

The Efficacy and Safety of Intradermal Acupuncture for Acute Herpes Zoster

Herpes zoster (HZ), also commonly known as shingles, is characterized by a bandlike rash in the dermatome that corresponds to the affected nerve. Pain is prevalent in HZ patients, which may be provoked by light touch. Postherpetic neuralgia (PHN) is one of the most common complications of HZ and it …

18 - 80 years of age Both Phase N/A
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

Background Shingles is a painful, blistering rash caused by the same virus that causes chickenpox. Shingrix is a vaccine approved to prevent shingles in healthy adults over age 50 and in immunocompromised adults over age 18. Researchers want to learn more about how people with HIV respond to Shingrix. Objective …

18 - 100 years of age Both Phase 1/2

The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)

This is a randomized, observer-blinded, active-controlled Phase I study to evaluate the safety, reactogenicity, and immunogenicity of REC610, when administered as 2 intramuscular (IM) injections in healthy adults aged 40 years and older, who do not have known HZ and history of varicella or HZ vaccination. The recombinant HZ vaccine, …

40 - 100 years of age Both Phase 1
K Katherine Gunn

A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 Years

This phase 1 study in Australia will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 Years.

50 - 70 years of age Both Phase 1

Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.

- 100 years of age Both Phase 2

Rewrite in simple language using AI